John Lantis, II

Dr. Fife completed a Family Medicine residency at the University of Texas, Southwestern in Dallas followed by a two-year Fellowship in Undersea and Hyperbaric Medicine at Duke University. Until 2013 she was a Professor of Medicine at the University of Texas Health Science Center, Houston where she initiated the Memorial Hermann Center for Wound Healing and Hyperbaric Medicine and the Lymphedema Center. She is now a Professor of Geriatrics at Baylor College of Medicine in Houston. She serves as the Chief Medical Officer of Intellicure, LLC, a health information technology company, and the Executive Director of the U.S. Wound Registry, a non-profit organization recognized by CMS as a qualified clinical data registry (QCDR). The USWR develops wound relevant quality measures and helps wound care practitioners meet the requirements of Medicare’s Quality Payment Program. She currently serves on the boards of the Alliance of Wound Care Stakeholders (past co-chair), and CLI Global Society, and she is on the American Diabetes Association's Amputation Prevention Coalition. She is co-chair of the Real World Evidence Work Group for the Wound Care Collaborative Community. Past board activities include the American Academy of Wound Management, the Association for the Advancement of Wound Care, and the American Professional Wound Care Association. She has authored more than 100 peer reviewed articles and book chapters as well as editing 3 textbooks.Her current focus is the use of real world data to find what works in the treatment of chronic wounds.

Dr. Lucian Vlad is an Associate Professor and Director of the Wound Care and Hyperbaric Fellowship at Atrium Health Wake Forest Baptist in Winston-Salem, NC. He is board-certified in Family Medicine, faculty in the Plastic & Reconstructive Surgery Department and has practiced full time in a tertiary wound care and hyperbaric center since 2012, with a clinical focus on limb salvage and complex chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure injuries. His academic interests span compression therapy, negative pressure wound therapy, collagen scaffolds and other advanced biologics, low-intensity laser and hyperbaric oxygen therapy, and clinical nutrition in wound care, and he is an active educator and frequent national and international lecturer.
Outside clinical work his advocay work includes ABWMS (American Board of Wound Medicine & Surgery) as member of the Board of Directors, WCCC (Wound Care Collaborative Community) as Chair of the Real Word Evidence Workstream, AAWC (Association for the Advancement of Wound Care) as Co-Chair of the Education Commitee and WHS (Wound Healing Society) member of Edducation Commitee.

Dr. Dove is the Director of Clinical Research at the Department of Orthopaedics, Division of Podiatry at UT Health Science San Antonio. Dr. Dove has served as a Principal Investigator in over 50 clinical trials, over the past twenty years. She is currently establishing a research program, in which her colleagues, residents and students will be actively engaged.

She earned the Degree of Doctor of Podiatric Medicine at California College of Podiatric Medicine in San Francisco, CA, She also completed her Post Graduate Training at The University of Texas, Health Science Center in San Antonio, Texas under the tutelage of Dr. Lawrence Harkless. She completed a surgical fellowship at North General Hospital, in New York, NY.

Dr. Dove was previously in private practice in Las Vegas. Her private practice combined industry sponsored research and general podiatry, with a focus on wound care. Before opening her practice, Dr. Dove was the director of podiatry at the Diabetic foot and Ankle Center - Hospital for Joint Disease - NYU. Concurrently, she served as the sub-investigator for multiple Phase I-IV clinical trials.

Dr. Dove has multiple publications, including the Lancet and other peer-reviewed journals.

Dr. Teresa L.Z. Jones is the Program Director for Diabetes Complications at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health in Bethesda, Maryland. Her research program at NIDDK is focused on basic science, translational and clinical studies on the diabetic lower extremity to improve our understanding of diabetic neuropathy and wound healing and the prevention and treatment of diabetic foot ulcers. She is the Project Scientist for the NIDDK Diabetic Foot Consortium whose initial goal is to validate prognostic, monitoring and diagnostic biomarkers for diabetic foot ulcers that can be used for clinical decision-making and therapy development. She is a board-certified endocrinologist who received her medical degree from Northwestern University Feinberg School of Medicine, completed her Internal Medicine residency at the University of Minnesota and her Endocrinology and Metabolism fellowship at the National Institutes of Health. She is the endocrine consultant for Whitman-Walker Health in Washington, DC.

John C. Lantis II, MD, is currently the site chief and professor of Surgery at Mount Sinai West Hospital and the Icahn School of Medicine in mid-town Manhattan, where he practices as a senior vascular surgeon. On January 1, 2024, he was named the director of advanced wound care, Department of Surgery, Mount Sinai Healthcare System. 
In 2023, he became the editor in chief of the journal WOUNDS; a Clinical Compendium. He is the past president of the New York Vascular Surgery Society, a founding member of the American Board of Wound Medicine and Surgery, and the Vascular Study Group of New York. 

Dr Painter-Hanson is a passionate, strategic leader and global operating executive with comprehensive expertise in transforming clinical research programs into data-driven commercial opportunities with impactful scientific output. Extensive experience in leading global medical and clinical affairs divisions for both industry and non-profit organizations, and management of and within clinical research organizations. Dr Painter-Hanson is a strong and effective collaborator with business partners, regulatory affairs, clinical operations, quality assurance, and R&D. 

Dr Painter-Hanson is an experienced leader of high-performing teams to achieve impactful evidence generation plans and successful global implementation in complex matrix environments. 

As a clinical assistant professor for the Department of Health at the University of Washington, Dr Painter-Hanson lectures, publishes internationally, and is a guest speaker on clinical epidemiology, clinical studies, and related topics at international scientific conferences. With a passion for clinical research, having published widely on topics related to clinical investigations in orthopedics and trauma, Dr Painter-Hanson is a medical doctor with 6 years of practicing experience in different specialties and health care systems. 

Dev is a plastic and reconstructive surgeon with 5+ years of FDA regulatory experience and specialized expertise in wound healing product development, combining clinical wound care expertise with comprehensive regulatory oversight of chronic wound therapeutics across the complete development lifecycle.

As FDA Medical Officer in CDER Division of Dermatology from 2020 - 2025 and Chair of the FDA Inter-Center Wound Healing Working Group, Dev led cross-agency regulatory strategy for wound healing products and organized a landmark 2022 FDA Wound Healing Scientific Workshop with 330+ stakeholders. He provided scientific oversight for innovative wound therapeutics from Pre-IND through NDA/BLA approval, with expertise in clinical trial design, endpoint validation, real-world evidence integration, and regulatory pathways for wound healing therapeutic indications. In addition, he served as CDER representative to the Wound Care Collaborative Community (WCCC). His clinical background includes managing patients with nonhealing chronic wounds and performing complex wound reconstruction surgeries, providing real-world understanding of treatment challenges and unmet medical needs.

In his new role as Senior Medical Director, Clinical Development at Oruka Therapeutics he is responsible for execution and operational oversight of clinical trials for psoriasis and hidradenitis suppurativa, ensuring high-quality data generation to support the safety and efficacy of pipeline products.

Dr Rachana Visaria is the Acting Director of the Division of Plastic and Reconstructive Surgery Devices within the Office of Surgical and Infection Control Devices (OHT4) at the FDA's Center for Devices and Radiological Health (CDRH). She holds a PhD in Bioengineering and is a Regulatory Affairs Certified (RAC) professional with over 10 years of experience in regulatory science, policy development, and total product lifecycle (TPLC) oversight. Her regulatory expertise spans diagnostic, monitoring, screening, and therapeutic products, including wound care devices, surgical implants, respiratory devices, digital health technologies, and neurostimulators. She has directed the review and evaluation of complex regulatory submissions including PMAs, De Novos, breakthrough device designations, and Medical Device Development Tool (MDDT) requests. She has authored numerous peer-reviewed publications and book chapters, including recent work on digital health regulation, and serves as FDA's primary liaison to several international standards working groups. Her commitment to regulatory excellence, stakeholder collaboration, and patient-centered innovation has been recognized through multiple CDRH awards.